Tue, March 1, 2011
Mon, February 28, 2011
Sun, February 27, 2011
Fri, February 25, 2011
Thu, February 24, 2011
Wed, February 23, 2011
Tue, February 22, 2011
[ Tue, Feb 22nd 2011 ]: Market Wire
PROTOX APPOINTS NEW DIRECTORS
Mon, February 21, 2011
Sun, February 20, 2011
Fri, February 18, 2011
Thu, February 17, 2011
Wed, February 16, 2011
Tue, February 15, 2011
Mon, February 14, 2011
Fri, February 11, 2011

MannKind to Present at the Citi 2011 Global Healthcare Conference

  Copy link into your clipboard //health-fitness.news-articles.net/content/2011/ .. -the-citi-2011-global-healthcare-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

VALENCIA, Calif.--([ BUSINESS WIRE ])--MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Citi 2011 Global Healthcare Conference on Tuesday, March 1, 2011 at 2:30 PM (ET) at the Hilton New York in New York, New York.

Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at [ http://www.mannkindcorp.com ].

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product candidate, AFREZZA(R), is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MannKind is also evaluating an investigational cancer immunotherapy product, MKC1106-MT, in a phase 2 clinical trial. MannKind maintains a website at [ http://www.mannkindcorp.com ] to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.